logo-loader
RNS
viewArix Bioscience PLC

Arix Bioscience Plc - Change of Broker

Arix Bioscience Plc - Change of Broker

Arix Bioscience Plc - Change of Broker

PR Newswire

Arix Bioscience plc

Change of Broker

LONDON, 07 November, 2019: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it has appointed Peel Hunt LLP as joint corporate broker, with immediate effect, alongside its existing corporate broker Jefferies International Limited.

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

[email protected]  

Optimum Strategic Communications

Mary Clark, Supriya Mathur

+44 (0)203 714 1787

[email protected]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

Quick facts: Arix Bioscience PLC

Price: 112.5

Market: LSE
Market Cap: £152.5 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aura Biosciences reports positive clinical data on its eye cancer treatment...

Aura Biosciences Inc CEO Elisabet de los Pinos tells Proactive Investors the biotech has reported positive clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light- activated AU-011, its lead product candidate for the treatment of choroidal melanoma, a type...

on 11/06/2018